Drug Safety 2018

SMi Group11 - 12 June 2018, London, UK.
SMi Group are delighted to announce their 5th Drug Safety conference. For drugs anywhere, it's the safety in patients which is a huge issue, constantly under surveillance, irrespective of where the drug is in its pipeline.

The Global Pharmaceutical Market currently has a market value of $1057 billion. If a drug is found to be unsafe, causing serious side effects, it can have a huge knock on effect on revenue, causing huge losses to pharmaceutical companies manufacturing the drug.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

Network and learn from leading professionals such as:

Keynote Speakers

  • David Lewis, Senior Adviser Pharmacovigilance, CMO Patient Safety, Novartis
  • Peter De Veene, Senior Vice President and Head Global Drug Safety and QPPV, Grünenthal
  • Simon Ashworth, VP EU QPPV, EU Head Compliance and Marketed Products and Head PV Affiliate Relations, Takeda

Regulatory Speaker

  • Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA

Pharmaceutical Speakers:

  • John Solomon, Head of Pharmacovigilance-UK & Ireland, Sanofi
  • Bjarke Naver, Head of Pharmacovigilance Science, LEO Pharma
  • Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen
  • Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical UK/IE/Malta and MENA, Accord Healthcare
  • Philip Eichorn, Senior Director, Worldwide Safety and Regulatory, Pfizer
  • Rawya Al Kredly, Director of Medical Affairs Department, Gulf Pharmaceutical Industries (Julphar)
  • Bert van Leeuwen, Deputy QPPV, Astellas
  • Kashif Sheikh, Safety Surveillance Specialist, Novo Nordisk

Featured Highlights:

  • MHRA spotlight presentation on the future of Clinical Trial Regulations
  • Hear first experiences with the new Eudravigilence system
  • Gain insight into how competitors are reporting adverse effects under the new legislation and system
  • Discuss risk-minimisation and signal detection strategies with industry-thought leaders
  • Evaluate the benefits and pitfalls of patient involvement and patient support programs

For further information and to register, please visit:
http://www.drugsafetyconference.co.uk/wpn

Early-Bird Rates

  • Book by 28th February and save £400
  • Book by 29th March and save £200
  • Book by 30th April and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...